New data released at the annual meeting of the American Psychiatric Association show that the NeuroStar TMS Therapy System® induced statistically and clinically meaningful response and remission in patients with Major Depressive Disorder (MDD) during the acute phase of therapy, which were maintained through one year of treatment.
Related Posts:
- Therapy Dogs Cure Stress at Hopkins Nursing
- Guidance for Clinicians on Prescribing Exercise for Depressed Patients
At the end of acute treatment, 62% of patients achieved symptomatic improvement while 41% reported complete remission. At 12 months, 68% of patients achieved symptomatic improvement while 45% reported complete remission. Maintenance of benefit was observed under a pragmatic regimen of continuation antidepressant medication and access to TMS reintroduction for symptom recurrence.
“The durability of NeuroStar TMS Therapy demonstrated by this robust, real-world study is remarkable, as it’s not typical to see long-term benefit in patients who have treatment resistant forms of depression,” said Dr. Philip Janicak, MD, Professor of Psychiatry at Rush University, and Medical Director of the Rush Psychiatric Clinical Research Center. “The study reinforces the sustained efficacy of NeuroStar TMS Therapy in a majority of patients with depression who have not found relief through oral antidepressant medication.”









May 22nd, 2013
John Buck










